Cas:147149-85-7 6-Amino-2-bromo-3-methylbenzoic acid manufacturer & supplier

Chemical Name:6-Amino-2-bromo-3-methylbenzoic acid

CAS.NO:147149-85-7

Synonyms:6-Amino-2-bromo-3-methylbenzoic acid;6-amino-2-bromo-3-methyl-benzoic acid;2-Amino-6-bromo-5-methylbenzoic acid;6-bromo-5-methylanthranilic acid;Benzoic acid,6-amino-2-bromo-3-methyl;Benzoic acid, 6-amino-2-bromo-3-methyl-

Molecular Formula:C₈H₈BrNO₂

Molecular Weight:230.059

HS Code:2922499990

Physical and Chemical Properties:

Melting point:N/A

Boiling point:353.6±42.0 °C at 760 mmHg

Density:1.7±0.1 g/cm3

Index of Refraction:1.651

PSA:63.32000

Exact Mass:228.973831

LogP:2.32

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 6-Amino-2-bromo-3-methylbenzoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Benzoic acid, 6-amino-2-bromo-3-methyl- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Benzoic acid, 6-amino-2-bromo-3-methyl- Use and application,6-amino-2-bromo-3-methyl-benzoic acid technical grade,usp/ep/jp grade.

Related News: Since the listing of high-barrier generic drugs involves quickly bypassing or challenging process patents of original research products within a short period of time, API companies play an important role in the process of marketing and sales of generic drugs. 6-Amino-2-bromo-3-methylbenzoic acid manufacturer The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. 6-Amino-2-bromo-3-methylbenzoic acid supplier All of China��s provinces and territories have now been touched by the outbreak. 6-Amino-2-bromo-3-methylbenzoic acid vendor All of China��s provinces and territories have now been touched by the outbreak. 6-Amino-2-bromo-3-methylbenzoic acid factory No amount of unmet need can take the place of sufficient evidence, said Johns Hopkins public health professor Dr. Caleb Alexander, a member of the FDA advisory panel.